Multiple sclerosis (MS) is a chronic autoimmune disorder affecting movement, sensation, and bodily functions. It is caused by destruction of the myelin insulation covering nerve fibers (neurons) in the central nervous system (brain and spinal cord).
A newer neuroimaging technique, magnetic resonance spectroscopy (MRS), has been useful in following NAA (N-acetyl-aspartate) levels in patients with multiple sclerosis. NAA is an amino acid found in neurons and axons of the mature brain. In patients with relapsing-remitting MS, NAA levels are reduced, suggesting axonal loss; however, in patients with secondary progressive MS with more disability, the NAA levels are reduced more significantly. In fact, patients with MS had lower levels of NAA even in areas of the brain previously thought to be unaffected, when compared with levels in normal persons.
Magnetic resonance imaging (MRI) remains the imaging procedure of choice for diagnosing and monitoring disease progression in the brain and spinal cord. This test can show brain abnormalities in 90–95% of patients and spinal cord lesions in up to 75% of cases, especially in elderly patients. However, MRI alone cannot be used to diagnose MS. Evoked potential tests that measure how quickly and accurately a person’s nervous system responds to certain stimulation have been the most useful neurophysiological studies for evaluation of MS.
Number of View: 3817